Angiotensin-Converting Enzyme I inhibitor and aldosterone antagonist.
It is prescribed in dogs for the treatment of congestive heart failure (CHF) caused by atrioventricular valve insufficiency (mitral and/or tricuspid) or by dilated cardiomyopathy.
The association of spironolactone and benazepril is beneficial as both act on the renin-angiotensin-aldosterone system (RAAS) but at different levels along the cascade. Benazepril, by preventing the formation of Angiotensin-Converting Enzyme, produces vasodilation and inhibits aldosterone secretion. Spironolactone, as an antagonist of aldosterone, blocks aldosterone escape and, thus, prevents the appearance of myocardial fibrosis and ventricular arrhythmias.